share_log

Todd Berard Sells 3,500 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

Todd Berard Sells 3,500 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

托德·貝拉德出售 3,500 股生物生活解決方案公司股票
Financial News Live ·  2023/01/28 05:39

BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) CMO Todd Berard sold 3,500 shares of BioLife Solutions stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $25.01, for a total value of $87,535.00. Following the completion of the transaction, the chief marketing officer now owns 119,265 shares of the company's stock, valued at approximately $2,982,817.65. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

生物生命解決方案公司(納斯達克代碼:BLFS-GET Rating)首席營銷官託德·貝拉德在1月23日(星期一)的交易中出售了3,500股生物生命解決方案公司的股票。這些股票的平均價格為25.01美元,總價值為87,535.00美元。交易完成後,首席營銷官現在擁有119,265股公司股票,價值約2,982,817.65美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站.

Todd Berard also recently made the following trade(s):

託德·貝拉德最近還進行了以下交易:

Get
到達
BioLife Solutions
生物生命解決方案
alerts:
警報:
  • On Wednesday, January 18th, Todd Berard sold 6,500 shares of BioLife Solutions stock. The shares were sold at an average price of $25.04, for a total value of $162,760.00.
  • On Wednesday, December 28th, Todd Berard sold 501 shares of BioLife Solutions stock. The shares were sold at an average price of $16.90, for a total value of $8,466.90.
  • On Thursday, November 10th, Todd Berard sold 50 shares of BioLife Solutions stock. The stock was sold at an average price of $23.16, for a total value of $1,158.00.
  • 1月18日,星期三,託德·貝拉德出售了6,500股BioLife Solutions的股票。這些股票的平均價格為25.04美元,總價值為162,760.00美元。
  • 12月28日,星期三,託德·貝拉德出售了501股BioLife Solutions股票。這些股票的平均價格為16.90美元,總價值為8466.90美元。
  • 11月10日,星期四,託德·貝拉德出售了50股BioLife Solutions的股票。這隻股票以23.16美元的平均價格出售,總價值為1158.00美元。

BioLife Solutions Trading Down 1.3 %

BioLife Solutions股價下跌1.3%

BLFS opened at $23.50 on Friday. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -9.48 and a beta of 1.75. BioLife Solutions, Inc. has a 52 week low of $10.40 and a 52 week high of $31.11. The business's 50 day moving average is $20.52 and its two-hundred day moving average is $21.37. The company has a quick ratio of 2.76, a current ratio of 3.68 and a debt-to-equity ratio of 0.06.

BLFS上週五開盤報23.50美元。該公司的市值為10.1億美元,市盈率為-9.48倍,貝塔係數為1.75。BioLife Solutions,Inc.的52周低點為10.40美元,52周高位為31.11美元。該業務的50日移動均線切入位為20.52美元,200日移動均線切入位為21.37美元。該公司的速動比率為2.76,流動比率為3.68,債務權益比為0.06。

BioLife Solutions (NASDAQ:BLFS – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The medical equipment provider reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The firm had revenue of $40.75 million for the quarter, compared to analyst estimates of $41.63 million. BioLife Solutions had a negative return on equity of 7.50% and a negative net margin of 67.70%. On average, research analysts predict that BioLife Solutions, Inc. will post -0.63 EPS for the current year.
生物生命解決方案公司(納斯達克代碼:BLFS-GET Rating)最近一次發佈季度收益報告是在11月9日星期三。這家醫療設備提供商報告該季度每股收益(0.15美元),低於(0.03美元)(0.12美元)的普遍預期。該公司本季度營收為4,075萬美元,而分析師預期為4,163萬美元。BioLife Solutions的股本回報率為負7.50%,淨利潤率為負67.70%。研究分析師平均預測,BioLife Solutions,Inc.本年度每股收益將為0.63美元。

Analyst Upgrades and Downgrades

分析師升級和下調評級

Several research firms recently weighed in on BLFS. Stephens decreased their target price on BioLife Solutions to $31.00 in a research note on Wednesday, November 16th. StockNews.com upgraded BioLife Solutions to a "sell" rating in a research note on Monday, November 21st.

幾家研究公司最近也加入了BLFS的行列。斯蒂芬斯在11月16日星期三的一份研究報告中將BioLife Solutions的目標價下調至31.00美元。在11月21日星期一的一份研究報告中,StockNews.com將BioLife Solutions的評級上調至“賣出”。

Institutional Inflows and Outflows

機構資金流入和流出

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in BioLife Solutions by 10.7% during the third quarter. BlackRock Inc. now owns 5,416,115 shares of the medical equipment provider's stock worth $123,217,000 after buying an additional 522,912 shares during the period. Vanguard Group Inc. increased its holdings in shares of BioLife Solutions by 14.8% in the third quarter. Vanguard Group Inc. now owns 2,415,511 shares of the medical equipment provider's stock valued at $54,953,000 after purchasing an additional 311,913 shares during the period. Fred Alger Management LLC increased its holdings in shares of BioLife Solutions by 21.9% in the third quarter. Fred Alger Management LLC now owns 2,163,476 shares of the medical equipment provider's stock valued at $49,219,000 after purchasing an additional 388,642 shares during the period. Millennium Management LLC increased its holdings in shares of BioLife Solutions by 45.3% in the second quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider's stock valued at $21,545,000 after purchasing an additional 486,631 shares during the period. Finally, Geneva Capital Management LLC increased its holdings in shares of BioLife Solutions by 5.8% in the third quarter. Geneva Capital Management LLC now owns 1,537,636 shares of the medical equipment provider's stock valued at $34,981,000 after purchasing an additional 84,435 shares during the period. Institutional investors and hedge funds own 89.82% of the company's stock.

幾家機構投資者最近增持或減持了該公司的股份。貝萊德股份有限公司在第三季度將其在BioLife Solutions的持倉增加了10.7%。貝萊德股份有限公司在此期間又購買了522,912股,目前持有這家醫療設備供應商5,416,115股股票,價值123,217,000美元。先鋒集團(Vanguard Group Inc.)第三季度增持BioLife Solutions股票14.8%。先鋒集團現在持有這家醫療設備供應商2,415,511股股票,價值54,953,000美元,在此期間又購買了311,913股。弗雷德·阿爾傑管理公司在第三季度增持了BioLife Solutions的股票21.9%。弗雷德·阿爾傑管理有限責任公司在此期間額外購買了388,642股,現在擁有這家醫療設備提供商2,163,476股股票,價值49,219,000美元。Millennium Management LLC在第二季度增持了BioLife Solutions的股票45.3%。Millennium Management LLC現在擁有這家醫療設備提供商的1,560,137股票,價值21,545,000美元,在此期間又購買了486,631股票。最後,日內瓦資本管理有限責任公司在第三季度增持了BioLife Solutions的股票5.8%。日內瓦資本管理有限責任公司現在擁有這家醫療設備提供商1,537,636股股票,價值34,981,000美元,在此期間又購買了84,435股。機構投資者和對衝基金持有該公司89.82%的股票。

About BioLife Solutions

關於BioLife解決方案

(Get Rating)

(獲取評級)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

BioLife Solutions,Inc.為美國、加拿大、歐洲、中東、非洲和國際上的細胞和基因治療行業開發、製造和提供生物生產工具和服務。該公司的產品用於基礎和應用研究,以及基於生物的療法的商業製造。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market
  • 免費獲取StockNews.com關於BioLife解決方案的研究報告(BLFS)
  • 市場回顧周-1/23-1/27
  • 為什麼Lucid在一天內飆升了近100%
  • 利用這些鐵路股票實現增長和收入
  • ASML預計今年芯片需求回升,提振銷售觀點
  • KLA公司:在動盪不安的半市場中站穩腳跟

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

每日收到有關BioLife解決方案的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioLife Solutions和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論